Physician profile
Jeffrey Owsley
NPI 1740629898
$23,036.15
in general payments reported to CMS, 2019-2025
40 companies · $3,649 in 2025
The $3,649 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $205 · 2021: $220 · 2022: $534 · 2023: $13K · 2024: $5,043 · 2025: $3,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $7,150 · Food and Beverage: $1,093 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,731.00 |
| Consulting Fee | $7,150.00 |
| Food and Beverage | $1,093.07 |
| Education | $236.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20,217.35 | 2019-2025 | Opdivo, Augtyro |
| Seagen INC. | $370.56 | 2019-2023 | Tukysa |
| Amgen INC. | $226.38 | 2019-2023 | Vectibix, Nplate, Xgeva |
| Lilly USA, LLC | $189.43 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $178.34 | 2019-2023 | Keytruda, Welireg, Lynparza |
| Novocure INC. | $170.40 | 2021-2022 | |
| Janssen Biotech, INC. | $168.51 | 2022-2025 | Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals LP | $151.04 | 2019-2024 | Tagrisso |
| Mirati Therapeutics, INC. | $104.64 | 2023 | Krazati |
| Exelixis INC. | $98.65 | 2019-2023 | Cabometyx |
| Sobi, INC | $95.26 | 2023 | |
| Pfizer INC. | $92.67 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.96 | 2019-2023 | |
| Astellas Pharma US INC | $74.99 | 2020 | |
| Pharmacosmos Therapeutics INC. | $69.92 | 2022-2023 | Monoferric |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Owsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.